Development of pure prolactin receptor antagonists

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Prolactin (PRL) is implicated in promoting tumor growth, prostate hyperplasia, and mammary neoplasia.
• Autocrine PRL signaling is increasingly recognized as a key factor in these proliferative processes.
• Existing PRL receptor antagonists often exhibit partial agonism, limiting their therapeutic efficacy.

Purpose of the Study:

• To develop novel human PRL antagonists with pure antagonistic properties, devoid of agonistic activity.
• To evaluate the efficacy of these new antagonists in vitro and in vivo models.
• To assess their potential for therapeutic intervention against PRL-mediated growth.

Main Methods:

• Development of new human PRL antagonist compounds.
• In vitro bioassays, including highly sensitive assays for receptor activation detection.
• In vivo studies assessing competitive inhibition of PRL-triggered signaling in target tissues (liver, mammary gland, prostate).
• Evaluation in transgenic mice with prostate-specific PRL expression exhibiting hyperplasia.

Main Results:

• The newly developed compounds demonstrated pure antagonism in vitro, with no detectable agonistic activity.
• These antagonists effectively inhibited PRL-triggered signaling cascades in vivo across multiple tissues.
• In transgenic mice, the PRL analogs completely reversed PRL-activated signaling and hyperplasia.

Conclusions:

• Novel, pure human PRL antagonists have been successfully developed.
• These second-generation antagonists exhibit potent efficacy in preclinical models.
• They represent promising candidates for inhibiting the growth-promoting actions of prolactin.